Catalyst Pharmaceuticals Stock Forecast, Price & News

-0.13 (-2.24 %)
(As of 06/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.06 million shs
Average Volume1.53 million shs
Market Capitalization$587.11 million
P/E Ratio8.35
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Catalyst Pharmaceuticals logo

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.26 out of 5 stars

Medical Sector

23rd out of 2,100 stocks

Pharmaceutical Preparations Industry

8th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

Is Catalyst Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Catalyst Pharmaceuticals stock.
View analyst ratings for Catalyst Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Catalyst Pharmaceuticals?

Wall Street analysts have given Catalyst Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Catalyst Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Catalyst Pharmaceuticals' next earnings date?

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Catalyst Pharmaceuticals

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its quarterly earnings results on Sunday, May, 9th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.09 by $0.02. The biopharmaceutical company had revenue of $30.21 million for the quarter, compared to the consensus estimate of $32.14 million. Catalyst Pharmaceuticals had a net margin of 60.11% and a trailing twelve-month return on equity of 27.81%.
View Catalyst Pharmaceuticals' earnings history

How has Catalyst Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CPRX shares have increased by 61.4% and is now trading at $5.68.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CPRX?

3 analysts have issued 1 year target prices for Catalyst Pharmaceuticals' stock. Their forecasts range from $5.50 to $11.00. On average, they expect Catalyst Pharmaceuticals' share price to reach $7.88 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price.
View analysts' price targets for Catalyst Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the following people:
  • Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 74, Pay $908.7k)
  • Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 59, Pay $643.31k)
  • Dr. Gary Ingenito, Chief Medical & Regulatory Officer (Age 65, Pay $646.75k)
  • Ms. Alicia Grande, Chief Accounting Officer, VP, Treasurer & CFO (Age 50)
  • Mr. Brian Elsbernd J.D., Chief Compliance Officer & Chief Legal Officer (Age 57)
  • Mr. Pete Curry Sr., VP of Sales
  • Mr. Jeffrey Del Carmen, Chief Commercial Officer (Age 50)
  • Mr. Philip B. Schwartz, Corp. Sec. (Age 66)
  • Dr. Charles W. Gorodetzky, Consultant (Age 83)

Who are some of Catalyst Pharmaceuticals' key competitors?

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.00%), Royce & Associates LP (3.14%), Prudential Financial Inc. (2.66%), Geode Capital Management LLC (1.71%), Goldman Sachs Group Inc. (1.38%) and LSV Asset Management (1.36%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Gary Ingenito and Patrick J Mcenany.
View institutional ownership trends for Catalyst Pharmaceuticals

Which institutional investors are selling Catalyst Pharmaceuticals stock?

CPRX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Man Group plc, AQR Capital Management LLC, D. E. Shaw & Co. Inc., Wedge Capital Management L L P NC, Schroder Investment Management Group, Credit Suisse AG, and JPMorgan Chase & Co..
View insider buying and selling activity for Catalyst Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Catalyst Pharmaceuticals stock?

CPRX stock was purchased by a variety of institutional investors in the last quarter, including Royce & Associates LP, Citigroup Inc., State Board of Administration of Florida Retirement System, BlackRock Inc., Dimensional Fund Advisors LP, Acadian Asset Management LLC, Rafferty Asset Management LLC, and Globeflex Capital L P. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, and Patrick J Mcenany.
View insider buying and selling activity for Catalyst Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $5.68.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals has a market capitalization of $587.11 million and generates $119.07 million in revenue each year. The biopharmaceutical company earns $74.98 million in net income (profit) each year or $0.40 on an earnings per share basis.

How many employees does Catalyst Pharmaceuticals have?

Catalyst Pharmaceuticals employs 74 workers across the globe.

What is Catalyst Pharmaceuticals' official website?

The official website for Catalyst Pharmaceuticals is

Where are Catalyst Pharmaceuticals' headquarters?

Catalyst Pharmaceuticals is headquartered at 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]

This page was last updated on 6/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.